Antigen PIPA and antibodies that bind thereto

Details Antigen PIPA and antibodies that bind thereto Antigen PIPA and antibodies that bind thereto

2008-07-29

2008-07-29

Harris, Alana M. (Department: 1643)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using tissue cell culture to make a protein or polypeptide

C435S320100, C435S330000, C536S023530, C424S130100, C424S141100, C424S143100, C530S387100, C530S388100, C530S388220

Reexamination Certificate

active

10713248

ABSTRACT:
Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.

REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5656444 (1997-08-01), Webb et al.
patent: 5665570 (1997-09-01), Yamagata et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5760185 (1998-06-01), Kimachi et al.
patent: 5773247 (1998-06-01), Maeda et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5932225 (1999-08-01), Wallach et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6110724 (2000-08-01), Nakagomi et al.
patent: 6117653 (2000-09-01), Thoma
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6221644 (2001-04-01), Berka et al.
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6406840 (2002-06-01), Li et al.
patent: 6416999 (2002-07-01), Li et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 0 519 596 (1992-12-01), None
patent: WO 97/35614 (1997-10-01), None
patent: WO-2004/043239 (2004-05-01), None
Bowie et al, Science, 247: 1306-1310, 1990.
Burgess et al, J. Cell Biology, 111 : 2129-2138, 1990.
Lazar et al, Molecular and Cellular Biology, 8: 1247-1252, 1988.
Dickman, S., Science, 280: p. 1196-1197, 1998.
Ianelli, C.J. et al, The Journal of Immunology, 159: 3910-3920, 1997.
Aruffo, A. et al. (1987). “Molecular Cloning of a CD 28 cDNA by a High-Efficiency COS Cell Expression System,”Proc. Natl. Acad. Sci USA84:8573-8577.
Bird, R. E. et al. (1988). “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Brown, B. A et al. (1987). “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Res.47:3577-3583.
Carter, P. et al. (1992). “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Nat. Acad. Sci USA89:4285-4289.
Co, M. S. et al. (1991). “Humanized Antibodies for Antiviral Therapy,”Proc. Nat. Acad. Sci USA88:2869-2873.
Co, M. S. et al. (1992). “Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen,”J. Immunol.148(4):1149-1154.
Coligan, J.E. et al., eds (1991). “Isolation of Proteins Using Antibodies,” InCurrent Protocols in Immunology, John Wiley & Sons, Inc., vol. 2, Supplement 18, pp. 8.2.1-8.2.9.
Daugherty, B. L. et al. (1991). “Polymerase Chain Reaction Facilitates the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD 18 Component of Leukocyte Integrins,”Nucl. Acids Res.19(9):2471-2476.
Dillman, R. O. et al. (1988). “Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug,”Cancer Research48:6097-6102.
Gorman, S. D. et al. (1991). “Reshaping a Therapeutic CD4 Antibody,”Proc. Nat. Acad. Sci USA88:4181-4185.
Jones, P. T. et al. (1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature321:522-525.
Kettleborough, C. A et al. (1991). “Humanization of a Mouse Monoclonal Antibody by CDR-grafting: Importance of Framework Residues on Loop Conformation,”Protein Engineering4(7):773-783.
Fu, Q. et al. (Mar. 2001). “Carbohydrate-Directed Conjugation of Cobra Venom Factor to Antibody by Selective Derivatization of the Terminal Galactose Residues,”Bioconjugate Chemistry12(2):271-279.
Göttlinger, H.G. et al. (Jul. 16, 1986). “The Epithelial Cell Surface Antigen 17-1A, A Target for Antibody-Mediated Tumor Therapy: Its Biochemical Nature, Tissue Distribution and Recognition by Different Monoclonal Antibodies,”International Journal of Cancer38(1):47-53.
Kreitman, R.J. (Dec. 2001). “Toxin-Labeled Monoclonal Antibodies,”Current Pharmaceutical Biotechnology2(4):313-325.
Park, K.R. et al. (Aug. 2000). “Anti-CD9 Monoclonal Antibody-Stimulated Invasion of Endometrial Cancer Cell Lines in vitro: Possible Inhibitory Effect of CD9 in Endometrial Cancer Invasion,”Molecular Human Reproduction6(8):719-725.
Supplementary European Search Report mailed May 19, 2006, for EP Application No. 03786664.7 filed Nov. 13, 2003, three pages.
Zimmermann, S. et al. (1997). “A Novel Immunotoxin Recognising the Epithelial Glycoprotein-2 has Potent Antitumoural Activity on Chemotherapy-Resistant Lung Cancer,”Cancer Immunology and Immunotherapy44(1):1-9.
Kohler, G. et al. (1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-497.
Lobuglio, A. F. et al. (1989). “Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response,”Proc. Natl. Acad. Sci. USA86:4220-4224.
Lowe (1979). “An Introduction to Affinity Chromatography,”InLaboratory Techniques in Biochemistry and Molecular Biology , North-Holland Publishing Company, Work , T. S. et al., eds., vol. 7 Part II, pp. 269-273 (Table of Contents Only).
Maeda, H. et al. (1991). “Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity,”Human Antibodies Hybridomas2:124-134.
Mahato, R. I. et al. (1997). “Cationic Lipic-Based Gene Delivery Systems: Pharmaceutical Perspectives,”Pharm. Res.14(7):853-859.
Mangham D. C. et al. (1999). “A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA),”Histopathology35(2):129-133.
Porath, J. et al. (1975). “Biospecific Affinity Chromatography and Related Methods,” Chapter 2 InThe Proteins, 3rdedition, Neurath, H. et al., eds. Academic Press, vol. 1 pp. 95-178.
Riechmann, L. et al. (1988). “Reshaping Human Antibodies for Therapy,”Nature332:323-327.
Shaw, D. R et al (1987). “Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen,”J. Immunol.138:4534-4538.
Shen, W-C et al. (1981). “CIS-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of Ph-Sensitive Linkage Releasing Drug From a Lysosomotropic Conjugate,”Biochem. Biophys Res. Commun102:1048-1054.
Stephan, J-P et al. (1999). “Distribution and Function of the Adhesion Molecule BEN During Rat Development,”Dev. Bio.212:264-277.
Stephan, J-P. et al. (1999). “Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation,”Endocrinology140(12):5841-5854.
Tempest, P. R. et al. (1991). “Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo,”Bio/Technology9:266-271.
Trouet, A. et al. (1982). “A Covalent Linkage Between Daunorubicin and Proteins That is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-Carrier Conjugate: In Vitro and In Vivo Studies,”Proc. Natl. Acad. Sci.79:626-629.
Verhoeyen, M. et al. (1988). “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,”Science239:1534-1536.
Weimer, L. M. et al. (2001). “Therapeutic Monoclonal Antibodies: General Principles,” Chapter 20, Section 5 InCancer: Principles and Practice of Oncology, 6thEdition, Freeman, Jr., Stuart, J. et al., eds. Lippincott Williams & Wilkins, pp. 495-508.
Wheatley, S. P. et al. (1998). “Indirect Immunofluorescence Microscopy in Cultured Cells,” Chapter 18 InAnimal Cel

Affiliated with

Also associated with

Rating

Antigen PIPA and antibodies that bind thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen PIPA and antibodies that bind thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen PIPA and antibodies that bind thereto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3936346